Clinical Trial Update: A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment [Phase 4]

View source ↗

Summary

Phase 4 pharmacokinetics study in Japanese epileptic patients with renal impairment assessing gabapentin post-marketing implications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Renal Impairment

Drugs mentioned

• Gabapentin (Gabapentin)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Renal Impairment | Phase 4 | Status: TERMINATED | Results posted: 2011-04-27